Radium‐223 Safety, Efficacy, and Concurrent Use with Abiraterone or Enzalutamide: First U.S. Experience from an Expanded Access Program

BACKGROUND. In the phase III ALSYMPCA trial, metastatic castration‐resistant prostate cancer (mCRPC) patients had few prior life‐prolonging therapies. Following ALSYMPCA, which demonstrated radium‐223 survival benefit, and before radium‐223 U.S. commercial availability, an expanded access program (E...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Sartor, Oliver, Vogelzang, Nicholas J., Sweeney, Christopher, Fernandez, Daniel C., Almeida, Fabio, Iagaru, Andrei, Brown, Alan, Smith, Matthew R., Agrawal, Manish, Dicker, Adam P., Garcia, Jorge A., Lutzky, Jose, Wong, Yu‐Ning, Petrenciuc, Oana, Gratt, Jeremy, Shore, Neal D., Morris, Michael J.
Formato: Artigo
Idioma:Inglês
Publicado em: AlphaMed Press 2017
Assuntos:
Genitourinary Cancer
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5813754/
https://ncbi.nlm.nih.gov/pubmed/29183960
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2017-0413
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados